Toll Free: 1-888-928-9744

Candidiasis - Pipeline Review, H2 2016

Published: Aug, 2016 | Pages: 151 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Candidiasis - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Candidiasis - Pipeline Review, H2 2016', provides an overview of the Candidiasis pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Candidiasis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Candidiasis and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Candidiasis
- The report reviews pipeline therapeutics for Candidiasis by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Candidiasis therapeutics and enlists all their major and minor projects
- The report assesses Candidiasis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Candidiasis

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Candidiasis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Candidiasis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
 Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Candidiasis Overview 8 Therapeutics Development 9 Pipeline Products for Candidiasis - Overview 9 Pipeline Products for Candidiasis - Comparative Analysis 10 Candidiasis - Therapeutics under Development by Companies 11 Candidiasis - Therapeutics under Investigation by Universities/Institutes 13 Candidiasis - Pipeline Products Glance 15 Late Stage Products 15 Clinical Stage Products 16 Early Stage Products 17 Unknown Stage Products 18 Candidiasis - Products under Development by Companies 19 Candidiasis - Products under Investigation by Universities/Institutes 22 Candidiasis - Companies Involved in Therapeutics Development 23 Amplyx Pharmaceuticals, Inc. 23 Bakker Medical Srl 24 Biomar Microbial Technologies 25 Biosergen AS 26 Cellceutix Corporation 27 Cidara Therapeutics, Inc. 28 Daewoong Pharmaceutical Co., Ltd. 29 Dermala Inc 30 General Biologicals Corporation 31 Grupo Ferrer Internacional, S.A. 32 Hsiri Therapeutics, LLC 33 iCo Therapeutics Inc. 34 Matinas BioPharma Holdings, Inc. 35 Nanomerics Ltd 36 Novabiotics Limited 37 NovaDigm Therapeutics, Inc. 38 Onxeo SA 39 Scynexis, Inc. 40 Sealife PHARMA GMBH 41 TGV-Laboratories 42 Viamet Pharmaceuticals, Inc. 43 Wellstat Vaccines, LLC 44 Candidiasis - Therapeutics Assessment 45 Assessment by Monotherapy Products 45 Assessment by Combination Products 46 Assessment by Target 47 Assessment by Mechanism of Action 49 Assessment by Route of Administration 51 Assessment by Molecule Type 53 Drug Profiles 55 (clotrimazole + diclofenac sodium) - Drug Profile 55 (clotrimazole + diclofenac sodium) 1 - Drug Profile 56 61894700 - Drug Profile 57 AC-17 - Drug Profile 58 amphotericin B - Drug Profile 59 amphotericin B - Drug Profile 61 amphotericin B - Drug Profile 64 Antibody to Target Ece1 for Candidiasis - Drug Profile 65 APX-001 - Drug Profile 66 arasertaconazole - Drug Profile 67 BSG-005 - Drug Profile 68 candidiasis vaccine - Drug Profile 69 CD-101 - Drug Profile 70 Cellullar Immunotherapy for Viral Infections and Fungal Infections - Drug Profile 73 CTIX-1502 - Drug Profile 74 Drug for Candidiasis - Drug Profile 75 DWP-06081 - Drug Profile 76 Forazoline A - Drug Profile 77 iCo-010 - Drug Profile 78 KSL-W - Drug Profile 79 MH-010 - Drug Profile 80 miconazole nitrate - Drug Profile 81 Monoclonal Antibodies for Candidiasis - Drug Profile 83 Monoclonal Antibody for Candidiasis - Drug Profile 84 Monoclonal Antibody for Candidiasis and Gram-Positive Bacterial Infections - Drug Profile 85 Monoclonal Antibody to Inhibit the Beta-Glucan for Fungal Infections - Drug Profile 86 mutanobactins - Drug Profile 87 Myc-102 - Drug Profile 88 NDV-3 - Drug Profile 89 NDV-3A - Drug Profile 91 NP-339 - Drug Profile 92 obliquumol - Drug Profile 93 Occidiofungin - Drug Profile 94 PAC-113 - Drug Profile 95 PMX-1408 - Drug Profile 97 PMX-1570 - Drug Profile 98 PMX-1576 - Drug Profile 99 PMX-1591 - Drug Profile 100 PMX-1625 - Drug Profile 101 PMX-519 - Drug Profile 102 PMX-70004 - Drug Profile 103 Recombinant Peptides for Oropharyngeal Candidiasis - Drug Profile 104 SCY-078 - Drug Profile 105 SLP-0901 - Drug Profile 108 SLP-0904 - Drug Profile 109 Small Molecule for Bacterial Vaginosis and Candidiasis - Drug Profile 110 Small Molecule for Fungal Infections - Drug Profile 111 Small Molecules for Aspergillosis and Candidiasis - Drug Profile 112 Small Molecules for Candidiasis - Drug Profile 113 Small Molecules for Candidiasis - Drug Profile 114 Small Molecules for Candidiasis - Drug Profile 115 Small Molecules for Fungal Infections - Drug Profile 116 Small Molecules for Fungal Infections - Drug Profile 117 Small Molecules for Systemic Candidiasis - Drug Profile 118 Synthetic Peptide to Inhibit CBL-B for Candidiasis - Drug Profile 119 Synthetic Peptides for Candidiasis - Drug Profile 120 Synthetic Peptides for Infections Diseases and Oncology - Drug Profile 121 TOL-463 - Drug Profile 122 Vaccine for Fungal Infections - Drug Profile 123 Vaccine to Target Ece1 for Candidiasis - Drug Profile 124 VT-1161 - Drug Profile 125 Candidiasis - Dormant Projects 129 Candidiasis - Discontinued Products 133 Candidiasis - Product Development Milestones 134 Featured News & Press Releases 134 Appendix 145 Methodology 145 Coverage 145 Secondary Research 145 Primary Research 145 Expert Panel Validation 145 Contact Us 145 Disclaimer 146
List of Tables
Number of Products under Development for Candidiasis, H2 2016 14 Number of Products under Development for Candidiasis - Comparative Analysis, H2 2016 15 Number of Products under Development by Companies, H2 2016 16 Number of Products under Development by Companies, H2 2016 (Contd..1) 17 Number of Products under Investigation by Universities/Institutes, H2 2016 19 Comparative Analysis by Late Stage Development, H2 2016 20 Comparative Analysis by Clinical Stage Development, H2 2016 21 Comparative Analysis by Early Stage Development, H2 2016 22 Comparative Analysis by Unknown Stage Development, H2 2016 23 Products under Development by Companies, H2 2016 24 Products under Development by Companies, H2 2016 (Contd..1) 25 Products under Development by Companies, H2 2016 (Contd..2) 26 Products under Investigation by Universities/Institutes, H2 2016 27 Candidiasis - Pipeline by Amplyx Pharmaceuticals, Inc., H2 2016 28 Candidiasis - Pipeline by Bakker Medical Srl, H2 2016 29 Candidiasis - Pipeline by Biomar Microbial Technologies, H2 2016 30 Candidiasis - Pipeline by Biosergen AS, H2 2016 31 Candidiasis - Pipeline by Cellceutix Corporation, H2 2016 32 Candidiasis - Pipeline by Cidara Therapeutics, Inc., H2 2016 33 Candidiasis - Pipeline by Daewoong Pharmaceutical Co., Ltd., H2 2016 34 Candidiasis - Pipeline by Dermala Inc, H2 2016 35 Candidiasis - Pipeline by General Biologicals Corporation, H2 2016 36 Candidiasis - Pipeline by Grupo Ferrer Internacional, S.A., H2 2016 37 Candidiasis - Pipeline by Hsiri Therapeutics, LLC, H2 2016 38 Candidiasis - Pipeline by iCo Therapeutics Inc., H2 2016 39 Candidiasis - Pipeline by Matinas BioPharma Holdings, Inc. , H2 2016 40 Candidiasis - Pipeline by Nanomerics Ltd, H2 2016 41 Candidiasis - Pipeline by Novabiotics Limited, H2 2016 42 Candidiasis - Pipeline by NovaDigm Therapeutics, Inc., H2 2016 43 Candidiasis - Pipeline by Onxeo SA, H2 2016 44 Candidiasis - Pipeline by Scynexis, Inc., H2 2016 45 Candidiasis - Pipeline by Sealife PHARMA GMBH, H2 2016 46 Candidiasis - Pipeline by TGV-Laboratories, H2 2016 47 Candidiasis - Pipeline by Viamet Pharmaceuticals, Inc., H2 2016 48 Candidiasis - Pipeline by Wellstat Vaccines, LLC, H2 2016 49 Assessment by Monotherapy Products, H2 2016 50 Assessment by Combination Products, H2 2016 51 Number of Products by Stage and Target, H2 2016 53 Number of Products by Stage and Mechanism of Action, H2 2016 55 Number of Products by Stage and Route of Administration, H2 2016 57 Number of Products by Stage and Molecule Type, H2 2016 59 Candidiasis - Dormant Projects, H2 2016 134 Candidiasis - Dormant Projects (Contd..1), H2 2016 135 Candidiasis - Dormant Projects (Contd..2), H2 2016 136 Candidiasis - Dormant Projects (Contd..3), H2 2016 137 Candidiasis - Discontinued Products, H2 2016 138



To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $2000
Multi User - US $4000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify